Mirum posts 'ground-breaking' Phase III data on Livmarli in PFIC

US biotech Mirum Pharmaceuticals (Nasdaq: MIRM) edged up 2.6% to $20.02 yesterday, as it released positive top-line data from its Phase III MARCH-PFIC clinical trial evaluating Livmarli (maralixibat) in rare pediatric disease progressive familial intrahepatic cholestasis (PFIC).

“The Livmarli data observed in the MARCH study showcase an unprecedented reduction in pruritus and serum bile acids. These data confirm our thesis that higher doses can result in improved efficacy and better outcomes for these patients,” said Chris Peetz, president and chief executive at Mirum.

The primary analysis was conducted in PFIC2 patients. The secondary analyses were evaluated in the All-PFIC cohort, which included PFIC2 as well as additional PFIC subtypes. The full-study population included All-PFIC as well as supplemental patients who had previously undergone surgery, had truncating mutations and other patients.